http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2304968-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d40960190e37af1e3390c21a67554f98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_229b16ec5283bd15703aa1d1ef0a748f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9239e9e0cd24d10b4707bcaef14d8392 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3afca0222b13e4902da00952b9cb4d8d |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4172 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-02 |
| filingDate | 2005-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2007-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7141f88819ba7c38238e0eb9b6d4d798 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fd7f6459652edcdfb7bbe716242f301 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16585e333c356f32083b5db5d8c218f8 |
| publicationDate | 2007-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2304968-C1 |
| titleOfInvention | Method for treating hodgkin's lymphoma |
| abstract | FIELD: medicine, oncology. n SUBSTANCE: it is necessary to fulfill the puncture of posterior section of iliac ala to sample 150 ml medullary suspension into the vial with 50 ml hemoconservant. The vial's content should be supplemented with 40 mg/sq. m doxorubicin, 600 mg/sq. m cyclophosphan and 1.4 mg/sq.m vincristine. The mixture obtained should be incubated at 37°C for 40 min. Then this mixture should be injected for a patient intravenously by drops. Then it is important to conduct infusion of 375 mg/sq.m dacarbazine on the 1 st d of therapy. Since the 1 st to the 10 th d they prescribe per 40 mg/sq. m prednisolone. On the 8 th d of therapy one should intravenously inject 10 mg/sq. m bleomycin. The course should be repeated in 14 d. The innovation enables to apply automyelochemotherapy on the 3d-4 th stage of systemic malignant disease as the main type of therapy by preventing the increased rate of aseptic necroses of capuit femoris in this category of patients due to the matched injection scheme. n EFFECT: higher efficiency of therapy. n 1 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2786699-C1 |
| priorityDate | 2005-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.